Skip to Content


In the US, Teduglutide (teduglutide systemic) is a member of the drug class miscellaneous GI agents and is used to treat Short Bowel Syndrome.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Drug acting on the gastrointestinal system

Chemical Name

[2-glycine](1-33)-Peptide 2 analogue of human glucagon (GLP-2) (WHO )

Foreign Names

  • Teduglutidum (Latin)
  • Teduglutid (German)
  • Téduglutide (French)
  • Teduglutida (Spanish)

Generic Names

  • Teduglutide (OS: USAN, BAN)
  • (Gly2)GLP-2 (IS)
  • ALX 0600 (IS)
  • UNII-7M19191IKG (IS)

Brand Names

  • Gattex
    NPS Pharmaceuticals, United States
  • Neotex
    Neopharm, Israel
  • Revertive
    Nycomed, Spain
  • Revestive
    NPS, Denmark; NPS Pharma, Germany; NPS Pharma, Sweden; NPS Pharma Holdings, Poland; NPS Pharma UK, United Kingdom; NPS Pharma UK Ltd., Ireland; Nycomed, Lithuania; Shire, France


BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.